2Johnson DH, Fehrenbacher L, Novotrry WF, et al. Randomized phase Ⅱ trial comparing bevacizumab plus carboplatin and paclitaxel with earboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol, 2004, 22:2184-2191. 被引量：1
3Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase Ⅱ trial. J Clin Oncol, 2005,23:3697-3705. 被引量：1
4Zhu X, Wu S, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis, 2007, 49 : 186-193. 被引量：1
8Mckenry LM,Salemo E.Pharmacology in Nursing[M]. 18th ed.St Louis: Mosby - Year Book Inc, 1992.1071. 被引量：1
9Wu Shenhong,Chen John J,Kudelka Andrzej,et al.Incidence and risk of hypertension with sorafenib in patients with cancer:a systematic review and meta-analysis[].The Lancet Oncology.2008 被引量：1
10Chu D,Lacouture ME,Fillos T,et al.Risk of hand-foot skin re-action with sorafenib:a systematic reviewand meta-analysis[].Acta Oncologica.2008 被引量：1
